English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Papillary thyroid cancer (PTC) is the most common malignant disease in endocrine systems. T-box transcription factor 22 (TBX22) is a phylogenetically conserved family member that has not been widely characterized in cancers. In this study, we explored the potential clinical significance and biological functions of  TBX22  in PTC. Comprehensive analyses of  TBX22  were based on the public databases and our local qRT-PCR cohort. We observed that  TBX22  was significantly downregulated in PTC compared with normal tissues.  TBX22  was associated with several clinicopathological factors in PTC. Low  TBX22  expression correlated with  BRAF   V 600 E   and TERT mutation. Functional enrichment analysis revealed that cancer-related pathways and immune progress were closely associated with  TBX22  in PTC. In TBX22-low PTC, high immune infiltration levels with increased CD8 +  T cells, natural killer, M1 macrophages, and T-regulatory cells were observed.  TBX22  was negatively correlated with the activity of different steps of the anticancer immunity cycle. Functionally, overexpression of  TBX22  inhibited the proliferation, invasion, and migration in PTC cells, while knocking down of  TBX22  showed the opposite effects. The present findings disclose that  TBX22 , as an immune microenvironment-related biomarker, could be an important tumor suppresser gene and might inform the management of PTC patients better.

T-Box Transcription Factor 22 Is an Immune Microenvironment-Related Biomarker Associated With the BRAFV600E Mutation in Papillary Thyroid Carcinoma